The prevention of ischemic stroke with antithrombotic drugs
Abstract
Current antithrombotic drugs reduce the risk of stroke, heart attack and death from vascular causes by 25 % in patients with cerebral ischemic events resulting from disease of small or large cerebral arteries. In the primary prevention, Acetylsalicylic acid (ASA) reduces the risk of stroke by 19 % in women but not in men. In patients with nonvalvular atrial fibrillation the risk of stroke treating with ASA is reduced by 20 %. Oral anticoagulants significantly reducestroke risk due to nonvalvular atrial fibrillation by 65–70 % compared with placebo and by 40 % compared with ASA alone. At the same time they cause more major bleedings. Recently studied new antiplatelet drugs and anticoagulants might alter the current course of stroke prevention treatment. Research is also needed on the benefits and risks of combination antiplatelets and anticoagulants in patients with non valvular atrial fibrillation in combination with arterial cerebral disease.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
